Explore

Trendline Trendline
Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position
Rapid Read Rapid Read
Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

A recent study presented at the ASCO conference revealed that Johnson & Johnson's drug Erleada (apalutamide) significantly improves outcomes for patients undergoing radical prostatectomy for high-risk localized prostate cancer. The study involved 2,109 participants and demonstrated that adding Erleada to the standard treatment regimen increased the likelihood of a complete or nearly complete response from 1% to 8.9%. Additionally, patients experienced a 29% lower risk of recurrence and a 20% lower risk of metastasis, with a median survival of 57.1 months compared to 38.4 months in the control group. The trial, which is the largest of its kind, suggests that Erleada could set a new standard for treating this type of cancer.
Rapid Read Rapid Read
Tune Therapeutics Unveils Promising Data for Hepatitis B Treatment at EASL 2026

Tune Therapeutics Unveils Promising Data for Hepatitis B Treatment at EASL 2026

Tune Therapeutics has presented positive Phase 1b/2a proof of concept data for TUNE-401, an epigenetic silencer for hepatitis B, at the European Association for the Study of Liver (EASL) Congress. The study demonstrated deep and durable antiviral activity, including direct silencing of cccDNA, a key barrier to curing chronic hepatitis B (CHB). TUNE-401, delivered intravenously, showed dose-dependent repression of HBV biomarkers and was well-tolerated in patients. The trial included single and multiple-dose cohorts, with biomarker repression observed in 100% of participants at higher dose levels. The study's findings suggest a potential pathway to a finite cure for HBV patients.
Rapid Read Rapid Read
Clinical Trials Show Promising Results for Cancer Treatment Injection

Clinical Trials Show Promising Results for Cancer Treatment Injection

Recent clinical trials have demonstrated promising results for a cancer treatment injection known as amivantamab, developed by Johnson & Johnson. The drug was tested in an 11-nation trial involving patients whose cancer had either spread or returned after other treatments failed. The trial included 102 patients with head and neck cancer, where tumors shrank or disappeared in 43 patients. Notably, 28 patients experienced tumor shrinkage, while 15 saw their tumors completely disappear. The injection has also shown similar results in patients with certain types of lung cancer, with tumors shrinking in more than a third of patients. The drug works by targeting a protein that aids tumor growth and blocking pathways used by cancer cells to resist treatment, while also activating the immune system to assist in treatment. The results of the trial are set to be presented at the American Society of Clinical Oncology annual meeting in Chicago.
Rapid Read Rapid Read
Beren Therapeutics Presents Promising Data on Adrabetadex for Niemann-Pick Disease at APMRF Conference

Beren Therapeutics Presents Promising Data on Adrabetadex for Niemann-Pick Disease at APMRF Conference

Beren Therapeutics, a leader in cholesterol trafficking biology, announced the presentation of six posters at the 2026 Ara Parseghian Medical Research Fund Conference. The focus is on adrabetadex, an investigational therapy for infantile-onset Niemann-Pick disease type C (I-NPC). The data presented includes both clinical and preclinical analyses, highlighting adrabetadex's potential as a disease-modifying treatment. The FDA has granted adrabetadex Breakthrough Therapy Designation, and it is currently under Priority Review with a target action date set for November 17, 2026. The conference also featured a fireside chat with Beren's CEO, Jason Camm, discussing the ongoing research and development efforts.
Trendline Trendline
Paradigm Health Launches New Clinical Trial Solution for Observational Study

Paradigm Health Launches New Clinical Trial Solution for Observational Study

Paradigm Health Launches New Clinical Trial Solution for Observational Study
Trendline Trendline
Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%
Rapid Read Rapid Read
Summit Therapeutics Faces Challenges with Ivonescimab Data at ASCO

Summit Therapeutics Faces Challenges with Ivonescimab Data at ASCO

Summit Therapeutics presented data on ivonescimab at the ASCO annual meeting, showing a 34% reduction in the risk of death in a Phase 3 lung cancer trial in Chinese patients. However, questions remain about the drug's efficacy in a more diverse U.S. population. The trial showed a four-month overall survival benefit, but the population was primarily young Chinese men with lung cancer who had smoked. Analysts are cautious about the drug's potential benefit in a global population, and Summit faces pressure to replicate the results in a broader Phase 3 trial.
Trendline Trendline
Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment
Trendline Trendline
Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment
Trendline Trendline
Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors

Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors

Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors
Rapid Read Rapid Read
Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients, showing an objective response rate of 81.3% in treatment-naïve and 87.1% in pre-treated patients. The drug demonstrated significant efficacy, particularly in patients with central nervous system metastases, achieving a 30% intracranial complete response rate. Lunbotinib fumarate was well tolerated, with minimal treatment-related adverse events leading to discontinuation.